Detailed interpretation of Seleniso (Silvio) instruction manual and usage guide

1. Introduction to drugs

Selinexor (trade name: 1) function, causing tumor suppressor proteins to accumulate in the nucleus, thereby inducing cancer cell apoptosis and inhibiting tumor growth. Selinisol is approved for the treatment of patients with multiple myeloma (MM) and refractory or relapsed mantle cell lymphoma (R/R MCL) and is an important targeted therapy option for patients with advanced hematological malignancies.

The advantage of selinesol is that it is easy to administer orally and can be used in combination with other drugs to improve the efficacy in patients with relapsed or refractory multiple myeloma. Clinical studies show that seliniso combined with low-dose dexamethasone (dexamethasone) can treat relapse/The overall response rate for refractory multiple myeloma can reach 20%~26%, and it has also shown significant efficacy in patients with refractory mantle cell lymphoma, providing a new treatment approach for patients with advanced hematological tumors.

2. Indications, usage and dosage

1.Indications

Combined with dexamethasone to treat patients with relapsed/ refractory multiple myeloma who have failed treatment with at least four regimens (including proteasome inhibitors, immunomodulators and anti-CD38monoclonal antibodies).

Single drug or combination therapy for patients with refractory mantle cell lymphoma (R/R MCL).

2.Usage and dosage

Multiple myeloma: The oral dose of selinesol is generally 80 mg twice weekly, combined with dexamethasone 20 mg orally.

Mantle cell lymphoma: Usual dosage is 60 mg once weekly, may be adjusted based on tolerability.

When taken orally, it is recommended to take it with food to reduce gastrointestinal irritation. At the same time, swallow the tablet whole without crushing or chewing.

3.Principles of dose adjustment

In patients with hepatic impairment or abnormal renal function, the dose should be adjusted based on specific laboratory indicators and clinical response.

In the event of severe hematological toxicity or non-hematological toxicity, temporary discontinuation of the drug, dose reduction, or extending the dosing interval may be considered. The specific plan should be in accordance with the doctor's advice.

3. Main side effects

Adverse reactions of selinesol are relatively common and require close monitoring and management by patients and physicians. Mainly include:

1.Hematological toxicity

Moderate to severe thrombocytopenia, anemia, and leukopenia are common side effects, and severe cases may lead to an increased risk of bleeding or infection.

It is recommended to review routine blood tests regularly and adjust dosage or suspend medication based on blood cell counts.

2.Gastrointestinal reactions

Nausea, vomiting, loss of appetite, and diarrhea are common and can be relieved by using antiemetics, eating in small portions, and nutritional support.

3.Fatigue and metabolic abnormalities

Fatigue, weakness, weight loss, hyponatremia, and hyperglycemia may occur, and vital signs and biochemical indicators need to be monitored.

4.Other side effects

Rare but potentially serious side effects include dehydration, hypotension, infection, and liver function abnormalities. If any abnormalities occur, seek medical attention promptly.

Compared with traditional chemotherapy drugs, the side effects of selinesol can be effectively controlled through dose adjustment, combined drugs and life management, but patients still need to self-monitor and undergo regular review.

4. Medication precautions

1.Combined medication and interactions

Avoid simultaneous use with potentCYP3A4 inhibitors or inducers to avoid affecting drug metabolism and causing an increase or decrease in blood drug concentration.

Can be used in combination with anti-nausea medications, nutritional supplements, etc. to improve tolerance.

2.Monitoring requirements

Blood routine: review before each medication and regularly during treatment to prevent serious hematological toxicity.

Liver and kidney function: Monitor every cycle or according to doctor’s recommendations to detect abnormalities in time.

Blood pressure, weight and water and electrolytes: especially elderly patients or those with underlying diseases need to pay attention.

3.Lifestyle and Medication Management

Maintain a regular schedule, ensure rest, and reduce fatigue.

Eat small and frequent meals to ensure nutritional intake and reduce the impact of nausea and vomiting on the body.

If abnormal symptoms occur, such as bleeding, infection, high fever or obvious fatigue, you should seek medical attention immediately.

4.Precautions for special groups of people

Elderly patients: The risk of hematological toxicity is high and monitoring should be strengthened.

Pregnant women and lactating women: There is insufficient data, the risks should be weighed, and in principle it is contraindicated.

5. Patient management and follow-up recommendations

1.Take medication as directed by your doctor: strictly follow the dose and time, and avoid missing doses or overdosing.

2.Regular review: Blood routine, liver and kidney function and electrolyte indicators need to be reviewed regularly.

3. Side effect management: Use anti-nausea drugs, nutritional supplements, fluid rehydration, etc. to control common side effects.

4.Life and psychological support: maintain a good lifestyle, receive psychological support when necessary, and improve treatment compliance.

Selinexor (Selinexor), as a new oral nuclear export inhibitor, has shown significant efficacy in the treatment of multiple myeloma and refractory mantle cell lymphoma. By strictly following the instructions for usage and dosage, regularly monitoring hematological and biochemical indicators, and rationally managing side effects, patients can ensure efficacy and safety to the greatest extent. For patients with advanced hematological tumors, selinesol provides a new treatment option and also emphasizes the importance of precise medication and full management.

Reference materials:https://www.drugs.com/